Humanitarian Horizons: Christina DiArcangelo Unveiled
As an active Bahai’ and mother to her one son, Christian, Christina DiArcangelo believes that listening, learning, and growing are everyday values that can change the world by impacting our own hearts, homes, and communities. Professionally, Christina wears many hats of a global clinical research pioneer, patient advocate, writer, publisher, podcast host, entrepreneur, and chief executive officer of multiple companies. All of the above lead her down a transformational path filled with challenges, pain, opportunity, and growth. This show helps educate, empower, and deliver hope.
Humanitarian Horizons: Christina DiArcangelo Unveiled
The Truth About Compounded GLP-1s: What Patients Need to Know | Christina DiArcangelo
Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.
In this episode of Humanitarian Horizons – Christina DiArcangelo Unveiled, Christina breaks down the growing concerns around compounded GLP-1 medications and what patients need to know to protect their health.
GLP-1 drugs like semaglutide and tirzepatide have become widely used for weight loss and metabolic health—but not all versions are the same. Christina explains the critical differences between FDA-approved GLP-1 medications and compounded alternatives, including concerns around safety, regulation, and patient awareness.
This episode highlights:
- The difference between FDA-approved and compounded GLP-1 medications
- Why clinical testing and manufacturing standards matter
- The importance of obtaining prescriptions through licensed healthcare providers
- The role of regulatory oversight in protecting patients
If you’re considering GLP-1 therapy, this is essential information to help you make informed decisions.
GLP-1, semaglutide, tirzepatide, compounded semaglutide, GLP-1 safety, FDA approved drugs, weight loss medication, diabetes medication, compounded pharmacy, patient safety, pharmaceutical regulation, clinical research, healthcare awareness, Christina DiArcangelo, humanitarian horizons, GLP-1 risks, medication safety
#GLP1 #Semaglutide #Tirzepatide #PatientSafety #HealthcareAwareness #FDA #WeightLoss #DiabetesCare #HumanitarianHorizons #ChristinaDiArcangelo